AAREY DRUGS & PHARM LTD
AAREYDRUGS · General/Diversified · NSE
₹88
Current Market Price
Fair Value (DCF)
₹21
Margin of Safety
-75.8%
Updated just now
YieldIQ Score
22/100
Piotroski F-Score
5/9
Economic Moat
None
Confidence
32%
ROE
—
Debt/Equity
0.38
WACC
11.1%
Market Cap
₹250 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
7.1%
Return on capital employed
EV / EBITDA
121.7×
Enterprise multiple
Debt / EBITDA
13.9×
Leverage vs earnings
Interest Coverage
2.6×
EBIT covers interest
Current Ratio
1.78×
Short-term liquidity
Asset Turnover
1.63×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-1.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹88.33
Bear case
₹12.18
MoS -625.2%
Base case
₹21.34
MoS -313.9%
Bull case
₹33.75
MoS -161.7%
Ratio Trends
AAREYDRUGS · last 4 annual periods
ROE
2.9%
ROCE
6.9%
Operating Margin
—
Debt / Equity
0.25×
PE
18.0×
EV / EBITDA
10.3×
Historical Financials
AAREYDRUGS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹492 Cr | ₹413 Cr | ₹395 Cr | ₹472 Cr | -1.3% |
| EBITDA | ₹13.9 Cr | ₹10.2 Cr | ₹11.4 Cr | ₹11.9 Cr | -5.1% |
| EBIT | — | — | — | — | — |
| PAT | ₹6.6 Cr | ₹3.8 Cr | ₹4.7 Cr | ₹4.0 Cr | -15.0% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹0.5 Cr | ₹-1.3 Cr | ₹-3.0 Cr | ₹10.3 Cr | +174.4% |
| CapEx | ₹-2.2 Cr | ₹-1.0 Cr | ₹-0.7 Cr | ₹-5.2 Cr | — |
| FCF | ₹-1.7 Cr | ₹-2.3 Cr | ₹-3.7 Cr | ₹5.1 Cr | — |
| Total Assets | ₹245 Cr | ₹291 Cr | ₹303 Cr | ₹291 Cr | +5.8% |
| Total Debt | ₹14.2 Cr | ₹37.7 Cr | ₹31.4 Cr | ₹34.9 Cr | +35.0% |
| Shareholders' Equity | ₹114 Cr | ₹117 Cr | ₹133 Cr | ₹138 Cr | +6.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AAREYDRUGS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| NECLIFE NECLIFE | — | — | Pending | -11.9% | — |
| BROOKS BROOKS | — | — | Pending | -10.2% | — |
| NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.2% | — |
| BAFNAPH BAFNAPH | — | — | Pending | 4.9% | — |
| MEDICO MEDICO | — | — | Pending | 16.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for AAREYDRUGS in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AAREYDRUGS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AAREYDRUGS →
Compare
Head-to-head with peers
Compare AAREYDRUGS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AAREYDRUGSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.